# E-DRUG: Table of contents of Prescrire International, August 1999

**URL:** <https://talk.edrugplus.org/t/e-drug-table-of-contents-of-prescrire-international-august-1999/5512>\
**Category:** e-drug\
**Created:** [July 9, 1999, 1:46pm UTC](https://talk.edrugplus.org/t/e-drug-table-of-contents-of-prescrire-international-august-1999/5512 "1999-07-09T13:46:46Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Prescrire\_Internatio](https://avatars.discourse-cdn.com/v4/letter/p/7c8e57/32.png) [@Prescrire\_Internatio](https://talk.edrugplus.org/u/Prescrire_Internatio)\
**Post date:** [July 9, 1999, 1:46pm UTC](https://talk.edrugplus.org/t/e-drug-table-of-contents-of-prescrire-international-august-1999/5512/1 "1999-07-09T13:46:46Z")

</div>

---------------------------------------------------  
E-DRUG Table of contents of Prescrire International, August 1999

Table of contents of Prescrire International, August 99 - Volume 8 � Nr. 42

Prescrire International is the English language edition of La revue  
Prescrire. It consists of a selection of articles of international interest  
from the monthly French-language journal La revue Prescrire. Prescrire  
International contains evaluations of new drugs and new indications,  
information on adverse effects, and assessments of therapeutic  
interventions.

EDITORIAL  
Medicine is real art!

NEW PRODUCTS

Orlistat (new preparation)  
Risk-benefit ratio not established

Pamidronic acid and Paget's disease (new indication)  
Possibly helpful in nonresponders to oral diphosphonates

Codeine for child pain (new preparation)  
Offers an advantage

Rituximab (new preparation)  
Encouraging results in follicular lymphoma

Etidronic acid and steroid therapy (new indication)  
No proven effect on the risk of fracture

Octreotide and bleeding oesophageal varices (new indication)  
No demonstrated superiority over terlipressin

ADVERSE EFFECTS

Valve disease due to appetite suppressants  
Mainly with dexfenfluramine and fenfluramine; exposed patients must be  
monitored

REVIEWS  
Cholesterol-lowering drugs  
Decision to treat depends on presence of coronary heart disease  
and LDL cholesterol levels

Flawed WHO recommendations on hypertension  
WHO flirtation with drug companies selling antihypertensives

Buprenorphine replacement therapy  
Confirmed efficacy for heroin addiction; teamwork of pharmacists  
and physicians is essential

Prescrire International is financed by subscription fees only. We cannot  
provide free subscriptions. If you do not know the journal we can send you  
a sample issue. Send us your name and address if you want to receive a  
sample issue of Prescrire International. An annual subscription covers six  
issues of Prescrire International plus an index to issues during the  
previous five years and costs $ 60 (FF 310) for individuals, $38 (FF 200)  
for students, and 360$ (FF1860) for commercial institutions.

Prescrire International  
Association Mieux Prescrire  
BP 459  
75527 Paris Cedex 11  
France  
Tel. 33 1 47 00 94 45  
Fax 33 1 48 07 87 32  
email : international@prescrire.org  
------=\_NextPart\_000\_01BEC9FD.AC735120  
Content-Type: text/html; charset=ISO-8859-1  
Content-Transfer-Encoding: quoted-printable

\<html\>\<head\>\</head\>\<BODY bgcolor=3D"#FFFFFF"\>\<p\>\<font size=3D2 =  
color=3D"#000000" face=3D"Arial"\>\<br\>\<br\>Table of contents of Prescrire =  
International, August 99 - Volume 8 =96 Nr. 42\<br\>\<br\>Prescrire =  
International is the English language edition of La revue\<br\>Prescrire. =  
It consists of a selection of articles of international interest\<br\>from =  
the monthly French-language journal La revue Prescrire. =  
Prescrire\<br\>International contains evaluations of new drugs and new =  
indications,\<br\>information on adverse effects, and assessments of =  
therapeutic\<br\>interventions.\<br\>\<br\>EDITORIAL\<br\>Medicine is real art! =  
&nbsp;&#009;&nbsp;&nbsp;\<br\>\<br\>\<br\>NEW PRODUCTS\<br\>\<br\>Orlistat (new =  
preparation) &#009;&nbsp;&nbsp;\<br\>Risk-benefit ratio not =  
established\<br\>\<br\>Pamidronic acid and Paget's disease (new indication) =  
&nbsp;&#009;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>Possibly helpful in =  
nonresponders to oral diphosphonates\<br\>\<br\>Codeine for child pain (new =  
preparation) &#009;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>Offers an =  
advantage\<br\>\<br\>Rituximab (new preparation) =  
&#009;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>Encouraging results in =  
follicular lymphoma\<br\>\<br\>Etidronic acid and steroid therapy (new =  
indication) &#009;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>No proven effect on =  
the risk of fracture\<br\>\<br\>Octreotide and bleeding oesophageal varices =  
(new indication) &#009;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>No demonstrated =  
superiority over terlipressin\<br\>\<br\>\<br\>ADVERSE EFFECTS\<br\>\<br\>Valve =  
disease due to appetite suppressants =  
&#009;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>Mainly with dexfenfluramine and =  
fenfluramine; exposed patients must be =  
monitored\<br\>\<br\>REVIEWS\<br\>Cholesterol-lowering drugs\<br\>Decision to =  
treat depends on presence of coronary heart disease\<br\>and LDL =  
cholesterol levels\<br\>\<br\>Flawed WHO recommendations on hypertension =  
&#009;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>WHO flirtation with drug =  
companies selling antihypertensives\<br\>\<br\>Buprenorphine replacement =  
therapy &#009;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\<br\>Confirmed efficacy for =  
heroin addiction; teamwork of pharmacists\<br\>and physicians is =  
essential\<br\>\<br\>\<br\>Prescrire International is financed by subscription =  
fees only. &nbsp;We cannot\<br\>provide free subscriptions. If you do not =  
know the journal we can send you\<br\>a sample issue. Send us your name =  
and address if you want to receive a\<br\>sample issue of Prescrire =  
International. An annual subscription covers six\<br\>issues of Prescrire =  
International plus an index to issues during the\<br\>previous five years =  
and costs $ 60 (FF 310) for individuals, $38 (FF 200)\<br\>for students, =  
and 360$ (FF1860) for commercial institutions.\<br\>\<br\>\<br\>Prescrire =  
International\<br\>Association Mieux Prescrire\<br\>BP 459\<br\>75527 Paris =  
Cedex 11\<br\>France\<br\>Tel. 33 1 47 00 94 45\<br\>Fax 33 1 48 07 87 =  
32\<br\>email : \<font =  
color=3D"#0000FF"\>\<u\>international@prescrire.org\</u\>\<font =  
color=3D"#000000"\>\</p\>  
\</font\>\</font\>\</font\>\</body\>\</html\>  
------=\_NextPart\_000\_01BEC9FD.AC735120--

--  
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.  
Mail administrative requests to `majordomo@usa.healthnet.org'.  
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.